Literature DB >> 7248163

Reduction of daunomycin toxicity by razoxane.

G Wang, M D Finch, D Trevan, K Hellmann.   

Abstract

A single dose of 200 mg/kg razoxane protected mice against the subchronic lethal effects (i.e. within 21 days) of 10 mg/kg daunomycin. When the razoxane dose was split into 2 doses of 100 mg/kg, even better protection against higher doses of daunomycin was obtained. The best protective effect was seen when the razoxane was given 24 h before or simultaneously with the daunomycin, and it was still present, though less, 24 h later. Histopathological examination to determine the site of protection showed it to be in the small bowel. Marrow and cardiac tissue showed no evident changes when examined by light microscopy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248163      PMCID: PMC2010720          DOI: 10.1038/bjc.1981.127

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  4 in total

1.  Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).

Authors:  E H Herman; R M Mhatre; D P Chadwick
Journal:  Toxicol Appl Pharmacol       Date:  1974-03       Impact factor: 4.219

2.  Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

Authors:  R J Woodman; R L Cysyk; I Kline; M Gang; J M Venditti
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

3.  Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.

Authors:  H Y Yap; R S Benjamin; G R Blumenschein; G N Hortobagyi; C K Tashima; A U Buzdar; G P Bodey
Journal:  Cancer Treat Rep       Date:  1979-01

4.  Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.

Authors:  J L Millar; B N Hudspith; T J McElwain; T A Phelps
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

  4 in total
  6 in total

Review 1.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

2.  Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.

Authors:  F A Bu'Lock; H M Gabriel; A Oakhill; M G Mott; R P Martin
Journal:  Br Heart J       Date:  1993-08

3.  Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.

Authors:  T Narita; S Yaguchi; T Komatsu; M Takase; A Hoshino; M Inaba; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Effect of high dose mitozantrone with Cronassial on the Lewis lung carcinoma and L1210 leukaemia.

Authors:  K Hellmann; G E Hutchinson; K Henry
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

5.  Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).

Authors:  T Narita; Y Koide; S Yaguchi; S Kimura; Y Izumisawa; M Takase; M Inaba; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.